Pharmaceuticals

HANSOH PHARMA

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

Hanson Pharma's HS-20093 Receives Breakthrough Therapy Designation from NMPA

Hansoh Pharmaceutical's Restricted Shares Trustee Buys Shares

Hanson Pharmaceuticals Transfers Exclusive License of Osteoarthritis Drug to Hengrui

Hanson Pharma Receives Breakthrough Therapy Designation for B7-H3 Targeted Antibody-Drug Conjugate

Hanson Pharma Receives Two Clinical Trial Approvals from NMPA

Hanson Pharma Terminates Old Share Plan and Proposes New One

Hanson Pharmaceuticals Grants 4.992 Million RSUs

Hanson Pharmaceutical's Annual Report Shows Significant Revenue Growth from Innovative Drugs, Ameile Boosts Performance

Hanson Pharma Announces Phase I Clinical Trial Results for HS-10504

Hansoh Pharmaceutical Announces 2025 Annual Report, Innovation Product Revenue Up 30.4%

CSC Financial Maintains Buy Rating for Hansoh Pharmaceutical

Hanson Pharma Announces HS-10506 Insomnia Treatment Phase 1b/2 Clinical Trial Results

Hanson Pharma's B7-H3 Targeted Antibody Drug Approved for Breakthrough Therapy in China

Hanson Pharmaceutical's XINYUE Approved for Myasthenia Gravis

Hanson Pharma Reports Strong 2025 Earnings, Revenue and Profit Grew Significantly

Huatai Pacific 上调 Hanson Pharma 2026-2027 年收入和利润预测

CLSA Cuts Target Price for Hansoh Pharmaceutical to HKD 40

Hanson Pharmaceutical Group Reports First Half of 2025 Fiscal Year Earnings

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

03692

Hansoh Pharmaceutical Group has received approval from China's National Medical Products Administration to begin clinical trials of its innovative drug HS-10541, targeting KRAS G12C-mutated advanced solid tumors. This marks a significant milestone in the company's strategy to enhance its oncology portfolio and strengthen its position in China's competitive market. Analysts rate the stock (HK:3692) as a Buy with a price target of HK$47.00, reflecting confidence in the company's growth potential in the biopharmaceutical sector.

Tip Ranks

Hansoh Pharma Wins NMPA Nod for Trial of New KRAS-Targeting Cancer Drug

Hansoh Pharmaceutical has received Breakthrough Therapy Designation from China's National Medical Products Administration for its drug HS-20093, aimed at treating unresectable locally advanced or metastatic esophageal squamous cell carcinoma. This designation may expedite the drug's development and review process, enhancing Hansoh's position in oncology and expanding its late-stage pipeline. Analysts rate the stock (HK:3692) as a Buy with a price target of HK$47.00. Hansoh focuses on innovative drug development, particularly in oncology, addressing significant unmet medical needs in Asia.

Hansoh Pharmaceutical Wins Breakthrough Therapy Status for Esophageal Cancer ADC

510660

512290

159316

159892

520690

516930

520500

513700

512010

159506

Hansoh Pharmaceutical Group (SEHK:3692) has achieved significant regulatory milestones, including Breakthrough-Therapy-Designated Drug status for HS-20093 and new trial approvals for HS-10522. Despite a recent 6.4% decline in share price, the company has shown strong long-term returns. Currently trading at a P/E of 35x, above industry averages, it raises questions about valuation. While some models suggest the stock is undervalued, risks remain due to high R&D costs and potential regulatory setbacks. Investors are advised to weigh both premium valuations and discounted cash flow estimates before making decisions.

Simplywall

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai CSI Bio-medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

First Trust NYSE Arca Biotech Index Fd

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI 300 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hansoh Pharmaceutical Group SEHK 3692 Valuation After New Breakthrough Therapy And Hypertension Trial Approvals

01276

Hansoh Pharmaceutical Group has transferred its exclusive Greater China license for KiOmed Pharma’s osteoarthritis treatment KiOmedine vs One to Jiangsu Hengrui Pharmaceuticals. This decision follows a strategic review of Hansoh's portfolio. The medical chitosan knee injection, approved by China's NMPA, will now be developed by Hengrui, which has a stronger orthopedic presence. The deal allows Hansoh to recover its development costs for RMB131 million and aligns with its long-term strategic focus. The latest analyst rating for Hansoh stock is a Buy with a price target of HK$47.00.

HENGRUI PHARMA

Hengrui Pharma

Hansoh Hands KiOmed Osteoarthritis Licence to Hengrui in Strategic Refocus

In a report released yesterday, from CSC Financial maintained a Buy rating on Hansoh Pharmaceutical Group Company Limited, with a price target of HK$48.73.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hansoh Pharmaceutical Group Company Limited with a HK$46.26 average price target.

CSC Financial Sticks to Its Buy Rating for Hansoh Pharmaceutical Group Company Limited (3692)

Hansoh Pharmaceutical Group has received NMPA approval for XINYUE's third indication, expanding its rare disease portfolio. The stock is currently priced at HK$39.4, reflecting a 21.6% return over 30 days and an 82.34% return over the past year. Despite strong earnings growth of 27.1%, the company's P/E ratio of 37.4x is significantly higher than industry averages, indicating potential overvaluation. However, a DCF analysis suggests shares may be undervalued at HK$39.4 compared to an estimated future cash flow value of HK$51.04. Investors should consider the mixed signals regarding valuation and growth expectations.

A Look At Hansoh Pharmaceutical Group’s Valuation As XINYUE Gains Third Rare Disease Approval In China

China's healthcare sector is attracting offshore capital to Hong Kong-listed stocks, with the Hang Seng Healthcare Index rising 13% since March 23, outperforming the benchmark Hang Seng Index's 6% gain. Investor interest has increased amid Middle East turmoil, as healthcare is less affected by commodity prices. Analysts noted strong earnings from large-cap pharmaceutical firms, with companies like Hansoh and Innovent leading the rally. The biotech subsector reported significant revenue and profit growth in 2025, driven by commercialization and licensing deals, contributing to a resilient performance in the sector.

SCMP

China healthcare stocks shine in Hong Kong amid Middle East turmoil

00460

513120

159570

520880

Hong Kong's innovative drug sector is experiencing significant growth, with companies like Ascletis Pharmaincreasing over 3% and Hansoh Pharmaceuticalrising by more than 2%. Other firms, including WuXi AppTecand Sihuan Pharmaceutical, are also showing upward trends.

CoinLive

SIHUAN PHARM

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ASCLETIS-B

WUXI APPTEC

Hong Kong's Innovative Drug Sector Gains Momentum

CICC analyst maintained a Buy rating on Hansoh Pharmaceutical Group Company Limited yesterday and set a price target of HK$52.00.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In a report released on April 2, CMB International Securities also maintained a Buy rating on the stock with a HK$46.41 price target.

CICC Keeps Their Buy Rating on Hansoh Pharmaceutical Group Company Limited (3692)

HANSOH PHARMA(03692.HK)